AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=120338&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class Action - AZN

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”). AstraZeneca investors have until February 21, 2025 to file a lead plaintiff motion. Investors suffering losses on their AstraZeneca investments are encouraged to contact the Law Offices of Ho.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC (AZN) Investors

NEW YORK , Jan. 2, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

AZN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES, CA / ACCESSWIRE / January 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.

AstraZeneca PLC Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Impacted Shareholders To Reach Out

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=120173&wire=1 or contact Joseph E. Levi, Esq.

AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN

LOS ANGELES , Jan. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws. Shareholders who bought the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.

AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZN

AbbVie

Johnson & Johnson

Eli Lilly

Pfizer

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.

5 Large Drug Stocks to Keep An Eye On in the New Year

NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming Deadlines - AZN

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=120074&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

AZN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119943&wire=1 or contact Joseph E. Levi, Esq.

February 21, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against AZN

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=120000&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / January 1, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=120032&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about pending Class Action - AZN

SAN FRANCISCO, Jan. 01, 2025 (GLOBE NEWSWIRE) -- AstraZeneca, the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class action lawsuit in the United States.

AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119840&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119832&wire=1 or contact Joseph E. Levi, Esq.

AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN

NEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 21, 2025 in the securities class action first filed by the Firm.

ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119815&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

AZN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / December 31, 2024 / AstraZeneca, the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class action lawsuit in the United States.

AstraZeneca (AZN) Reels from China Investigation and Investor Suit - Hagens Berman

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119782&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by February 21, 2025 Deadline to Join Class Action Against AstraZeneca PLC (AZN)

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119744&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of AstraZeneca PLC (AZN) of a Class Action Lawsuit and an Upcoming Deadline

LOS ANGELES , Dec. 31, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.

AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=119589&wire=1 or contact Joseph E. Levi, Esq.

News for AstraZeneca Stock (AZN)